The role of aspirin in the prevention of cardiovascular disease
- PMID: 24573704
- PMCID: PMC4317158
- DOI: 10.3121/cmr.2013.1197
The role of aspirin in the prevention of cardiovascular disease
Abstract
Aspirin therapy is well-accepted as an agent for the secondary prevention of cardiovascular events and current guidelines also define a role for aspirin in primary prevention. In this review, we describe the seminal trials of aspirin use in the context of current guidelines, discuss factors that may influence the effectiveness of aspirin therapy for cardiovascular disease prevention, and briefly examine patterns of use. The body of evidence supports a role for aspirin in both secondary and primary prevention of cardiovascular events in selected population groups, but practice patterns may be suboptimal. As a simple and inexpensive prophylactic measure for cardiovascular disease, aspirin use should be carefully considered in all at-risk adult patients, and further measures, including patient education, are necessary to ensure its proper use.
Keywords: Aspirin/history/therapeutic use; Cardiovascular diseases/drug therapy; Coronary artery disease; Non-steroidal anti-inflammatory agents.
© 2013 Marshfield Clinic.
Similar articles
-
Cardiovascular pharmacology core reviews: aspirin.J Cardiovasc Pharmacol Ther. 2013 Nov;18(6):505-13. doi: 10.1177/1074248413503043. Epub 2013 Sep 19. J Cardiovasc Pharmacol Ther. 2013. PMID: 24057863 Review.
-
Budget Impact of Appropriate Low-Dose Aspirin Use for Primary and Secondary Cardiovascular Event Prevention in the Managed Care Setting.J Manag Care Spec Pharm. 2018 Nov;24(11):1102-1111. doi: 10.18553/jmcp.2018.24.11.1102. J Manag Care Spec Pharm. 2018. PMID: 30362916 Free PMC article.
-
An aspirin a day? Aspirin use across a spectrum of risk: cardiovascular disease, cancers and bleeds.Expert Opin Pharmacother. 2014 Feb;15(2):153-7. doi: 10.1517/14656566.2014.853039. Epub 2013 Nov 11. Expert Opin Pharmacother. 2014. PMID: 24206142
-
Aspirin for primary prevention of cardiovascular disease?Drug Ther Bull. 2009 Nov;47(11):122-5. doi: 10.1136/dtb.2009.10.0045. Drug Ther Bull. 2009. PMID: 19887685
-
Role of ASA in the primary and secondary prevention of cardiovascular events.Best Pract Res Clin Gastroenterol. 2012 Apr;26(2):113-23. doi: 10.1016/j.bpg.2012.01.013. Best Pract Res Clin Gastroenterol. 2012. PMID: 22542150 Review.
Cited by
-
Aspirin in Primary Prevention of Cardiovascular Events.Clin Med Res. 2020 Aug;18(2-3):89-94. doi: 10.3121/cmr.2020.1548. Epub 2020 Jun 24. Clin Med Res. 2020. PMID: 32580960 Free PMC article. Review.
-
Prevention of aspirin-mediated secondary toxicity by combined treatment of carotenoids in macrophages.3 Biotech. 2023 Jul;13(7):223. doi: 10.1007/s13205-023-03632-w. Epub 2023 Jun 6. 3 Biotech. 2023. PMID: 37292139 Free PMC article.
-
The Role of the Vascular System in Degenerative Diseases: Mechanisms and Implications.Int J Mol Sci. 2024 Feb 11;25(4):2169. doi: 10.3390/ijms25042169. Int J Mol Sci. 2024. PMID: 38396849 Free PMC article. Review.
-
Zofenopril versus ramipril in the early phase of acute myocardial infarction with systolic dysfunction: A retrospective study.J Renin Angiotensin Aldosterone Syst. 2020 Jul-Sep;21(3):1470320320946530. doi: 10.1177/1470320320946530. J Renin Angiotensin Aldosterone Syst. 2020. PMID: 32883157 Free PMC article.
-
Aspirin inhibits rotavirus replication and alters rat gut microbial composition.Virol J. 2023 Oct 17;20(1):237. doi: 10.1186/s12985-023-02199-5. Virol J. 2023. PMID: 37848986 Free PMC article.
References
-
- Soni A. Aspirin use among the adult U.S. non institutionalized population, with and without indicators of heart disease, 2005. Statistical Brief #129. Agency for Healthcare Research and Quality, Medical Expenditure Panel Survey; Available at: http://meps.ahrq.gov/mepsweb/data_files/publications/st179/stat179.pdf Accessed February 6, 2013.
-
- Fuster V, Sweeny JM. Aspirin: a historical and contemporary therapeutic overview. Circulation 2011;123:768–778. - PubMed
-
- Dippel DW, Van Kooten F, Leebeek FW, van Vilet HH, Mehicevic A, Li SS, Koudstaal PJ. What is the lowest dose of aspirin for maximum suppression of in vivo thromboxane production after a transient ischemic attack or ischemic stroke? Cerebrovasc Dis 2004;17:296–302. - PubMed
-
- Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: a meta-analysis on 376,162 patients. Am J Med 2012;125:882–887.e1. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials